Tagged Articles

febuxostat 2 articles

Increased risk of death with gout drug Uloric

People treated with the gout drug febuxostat, known by the brand name Uloric, are at an increased risk of death compared to those taking the gout medicine allopurinol, the Food and Drug Administration (FDA) cautioned in a safety communication. The agency is requiring a boxed warning – its most serious warning – be added to the safety label of febuxostat based on a review of a large, post-market safety study. “This conclusion is based on our in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and death from all causes with Uloric,” ... Read More

Gout medication linked to heart-related death

Preliminary results from a clinical trial show that patients taking the gout medication febuxostat (brand name Uloric) were at greater risk of heart-related death than patients taking another gout medication called allopurinol, the Food and Drug Administration (FDA) announced in a safety communication. The agency had ordered Uloric’s maker, Takeda Pharmaceuticals, to conduct a safety study when the medication was approved in 2009 to better understand its risks. The agency is still evaluating the data and will update the public once the final results are available from Takeda and a comprehensive review is conducted. Febuxostat already carries a warning about ... Read More